Karuna Therapeutics (Karuna Therapeutics) GF Value : $0.00 (As of Jun. 01, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-06-01), Karuna Therapeutics's share price is $329.83. Karuna Therapeutics's GF Value is $0.00. Therefore, Karuna Therapeutics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Karuna Therapeutics is Not Valued.

Karuna Therapeutics (NAS:KRTX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Karuna Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	329.83	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karuna Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Karuna Therapeutics (Karuna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

KRTX:Mexico

Address

99 High Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.karunatx.com

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

Executives

Stephen K. Brannan	officer: Chief Medical Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown	officer: Chief Financial Officer	KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller	officer: Chief Operating Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr	officer: Chief Commercial Officer	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury	director, officer: President and CEO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins	officer: Chief Commercial Officer	C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul	director, officer: President & CEO	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045